Pharmaceutical patent litigators are no strangers to the delicate dance between the Hatch-Waxman Act and 35 U.S.C. § 271(b).
Koshy Mathai is the IMF’s Resident Representative in Sri Lanka. Opinions expressed in articles and other materials are those of the authors; they do not necessarily reflect IMF policy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results